Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Kiniksa Pharmaceuticals Company

KNSA
BMG5269C1010
A2JMVJ

Price

26.26
Today +/-
-0.45
Today %
-1.85 %
P

Kiniksa Pharmaceuticals stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Kiniksa Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Kiniksa Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Kiniksa Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Kiniksa Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Kiniksa Pharmaceuticals Stock Price History

DateKiniksa Pharmaceuticals Price
10/18/202426.26 undefined
10/17/202426.75 undefined
10/16/202426.32 undefined
10/15/202427.06 undefined
10/14/202426.63 undefined
10/11/202426.56 undefined
10/10/202425.49 undefined
10/9/202424.93 undefined
10/8/202424.47 undefined
10/7/202423.73 undefined
10/4/202424.48 undefined
10/3/202424.29 undefined
10/2/202424.53 undefined
10/1/202425.47 undefined
9/30/202424.99 undefined
9/27/202425.00 undefined
9/26/202423.96 undefined
9/25/202424.10 undefined
9/24/202424.45 undefined
9/23/202424.62 undefined

Kiniksa Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Kiniksa Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Kiniksa Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Kiniksa Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Kiniksa Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Kiniksa Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Kiniksa Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Kiniksa Pharmaceuticals’s growth potential.

Kiniksa Pharmaceuticals Revenue, EBIT and net profit per share

DateKiniksa Pharmaceuticals RevenueKiniksa Pharmaceuticals EBITKiniksa Pharmaceuticals Net Income
2029e965.94 M undefined0 undefined73.08 M undefined
2028e750.8 M undefined84.66 M undefined62.95 M undefined
2027e795.02 M undefined81.63 M undefined98.77 M undefined
2026e695.92 M undefined70.03 M undefined55.23 M undefined
2025e585.17 M undefined47.86 M undefined43.96 M undefined
2024e429.59 M undefined-13.29 M undefined-14.29 M undefined
2023270.26 M undefined-25.2 M undefined14.08 M undefined
2022220.2 M undefined9.8 M undefined183.4 M undefined
202138.5 M undefined-156.6 M undefined-157.9 M undefined
20200 undefined-157.4 M undefined-161.4 M undefined
20190 undefined-170 M undefined-161.9 M undefined
20180 undefined-108.2 M undefined-103.2 M undefined
20170 undefined-65.4 M undefined-64.9 M undefined
20160 undefined-24 M undefined-24 M undefined

Kiniksa Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201620172018201920202021202220232024e2025e2026e2027e2028e2029e
0000038220270429585695795750965
------478.9522.7358.8936.3618.8014.39-5.6628.67
-----76.3289.5587.41------
0000029197236000000
-24-65-108-170-157-1569-25-13477081840
------410.534.09-9.26-3.038.0310.0710.1911.20-
-24-64-103-161-161-15718314-144355986273
-166.6760.9456.31--2.48-216.56-92.35-200.00-407.1427.9178.18-36.7317.74
48.448.449.55461.868.670.471.92000000
--------------
Details

Keystats

ⓘ

Revenue and Growth

The Kiniksa Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Kiniksa Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20162017201820192020202120222023
               
5645.6307.3233.4323.5182.2190.6206.37
00000420.321.27
00000000
000003.721.631.12
0.41.56.48.29.86.610.517.54
56.447.1313.7241.6333.3196.5243276.3
0.10.16.48.310.68.4712.67
00000000
00000000
0000019.318.317.25
00000000
00.31.94.65.68.7191.3220.11
0.10.48.312.916.236.4216.6250.03
56.547.5322254.5349.5232.9459.6526.32
               
79.9119.8000000.02
0.41.3473.5581.5829.4860.5888.1916.76
-26.1-91-194.2-356.1-517.5-675.4-492-477.95
00000-10006
00000000
54.230.1279.3225.4311.9185396.1438.84
0.21.210.95.70.51.97.98.25
2.116.231.422.131.341.433.446.92
000.2001.55.88.5
00000000
00000000
2.317.442.527.831.844.847.163.67
00000000
00000000
000.11.35.72.916.523.82
000.11.35.72.916.523.82
2.317.442.629.137.547.763.687.48
56.547.5321.9254.5349.4232.7459.7526.32
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Kiniksa Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Kiniksa Pharmaceuticals's financial health and stability.

Assets

Kiniksa Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Kiniksa Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Kiniksa Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Kiniksa Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20162017201820192020202120222023
-23-64-103-161-161-15718314
00022222
000-340-185-33
11318-17-40-221
01103643535356
00000000
000101105
-21-50-81-158-136-126513
00-5-30-2000
00-23949-23128-8-29
00-23352-23149-7-29
00000000
00000000
423935084228523
423934684227521
---3.00--1.00---2.00
00000000
20-1026-256780-14
-21.87-50.29-86.3-161.57-136.81-146.725.713.17
00000000

Kiniksa Pharmaceuticals stock margins

The Kiniksa Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Kiniksa Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Kiniksa Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Kiniksa Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Kiniksa Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Kiniksa Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Kiniksa Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Kiniksa Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Kiniksa Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Kiniksa Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Kiniksa Pharmaceuticals Margin History

Kiniksa Pharmaceuticals Gross marginKiniksa Pharmaceuticals Profit marginKiniksa Pharmaceuticals EBIT marginKiniksa Pharmaceuticals Profit margin
2029e87.64 %0 %7.57 %
2028e87.64 %11.28 %8.38 %
2027e87.64 %10.27 %12.42 %
2026e87.64 %10.06 %7.94 %
2025e87.64 %8.18 %7.51 %
2024e87.64 %-3.09 %-3.33 %
202387.64 %-9.32 %5.21 %
202289.6 %4.45 %83.29 %
202176.36 %-406.75 %-410.13 %
202087.64 %0 %0 %
201987.64 %0 %0 %
201887.64 %0 %0 %
201787.64 %0 %0 %
201687.64 %0 %0 %

Kiniksa Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Kiniksa Pharmaceuticals earnings per share therefore indicates how much revenue Kiniksa Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Kiniksa Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Kiniksa Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Kiniksa Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Kiniksa Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Kiniksa Pharmaceuticals Revenue, EBIT and net profit per share

DateKiniksa Pharmaceuticals Sales per ShareKiniksa Pharmaceuticals EBIT per shareKiniksa Pharmaceuticals Earnings per Share
2029e13.62 undefined0 undefined1.03 undefined
2028e10.58 undefined0 undefined0.89 undefined
2027e11.21 undefined0 undefined1.39 undefined
2026e9.81 undefined0 undefined0.78 undefined
2025e8.25 undefined0 undefined0.62 undefined
2024e6.06 undefined0 undefined-0.2 undefined
20233.76 undefined-0.35 undefined0.2 undefined
20223.13 undefined0.14 undefined2.61 undefined
20210.56 undefined-2.28 undefined-2.3 undefined
20200 undefined-2.55 undefined-2.61 undefined
20190 undefined-3.15 undefined-3 undefined
20180 undefined-2.19 undefined-2.08 undefined
20170 undefined-1.35 undefined-1.34 undefined
20160 undefined-0.5 undefined-0.5 undefined

Kiniksa Pharmaceuticals business model

Kiniksa Pharmaceuticals Ltd is a US biotech company founded in 2015 and headquartered in Lexington, Massachusetts. The company specializes in the development and commercialization of therapies for rare and chronic inflammatory diseases. Kiniksa Pharmaceuticals' business model is based on collaboration with leading scientists and clinicians to develop innovative solutions for patients with complex clinical needs. The company's products focus on various inflammatory diseases and have multiple candidates in the pipeline for different indications in clinical development. Kiniksa Pharmaceuticals has also focused on developing therapies for rare diseases. A key feature of the company is its high-throughput platform, which allows for the identification and validation of potential therapeutics in a short amount of time. Kiniksa Pharmaceuticals was founded in 2015 by former executives from Biogen and Vertex Pharmaceuticals who had extensive experience in the discovery and development of drugs for chronic inflammatory diseases. The company quickly received an initial funding of $60 million and has since sought additional financing to expand its technology platform and scientific expertise. Kiniksa Pharmaceuticals consists of several divisions, including the development division, which is responsible for the clinical development of therapeutics for rare and chronic inflammatory diseases. Another important division is product development, which specializes in the identification and validation of candidates for potential therapeutics. This includes the identification of biomarkers that can serve as indicators of drug effectiveness. Kiniksa Pharmaceuticals also has a marketing division responsible for the commercialization of already approved products. The products of Kiniksa Pharmaceuticals focus on the treatment of inflammatory diseases. One of the key candidates currently in clinical development is KPL-716, a potential monoclonal antibody that can be used for multiple indications, including cutaneous T-cell lymphoma and chronic obstructive asthma. Another important potential is the candidate Mavrilimumab, a potential monoclonal antibody that can be used for the treatment of giant cell arteritis and polymyalgia rheumatica. Other key candidates include KPL-404, a potential monoclonal antibody that can be used for the treatment of ulcerative colitis. Overall, Kiniksa Pharmaceuticals has a promising future by focusing on innovative products for rare and chronic inflammatory diseases. Kiniksa Pharmaceuticals is one of the most popular companies on Eulerpool.com.

Kiniksa Pharmaceuticals SWOT Analysis

Strengths

Kiniksa Pharmaceuticals Ltd benefits from several key strengths that contribute to its success and competitive advantage. These include:

  • Strong research and development capabilities, enabling the company to innovate and develop new drugs.
  • Well-established relationships with key opinion leaders and healthcare professionals, facilitating the company's access to market insights and collaboration opportunities.
  • Reputation for delivering high-quality pharmaceutical products, fostering trust and loyalty among customers and stakeholders.
  • Solid financial position and access to capital, allowing for investment in extensive clinical trials and commercialization efforts.

Weaknesses

Despite its strengths, Kiniksa Pharmaceuticals Ltd also faces certain weaknesses that pose challenges for the company's growth and competitiveness. These weaknesses include:

  • Limited product portfolio, relying heavily on a few key drugs, which exposes the company to the risk of market fluctuations and patent expiry.
  • Relatively small scale compared to some competitors, limiting the company's ability to invest in extensive marketing campaigns and penetrate larger markets.
  • Dependence on third-party suppliers for raw materials and components, making the company vulnerable to supply chain disruptions and price fluctuations.
  • Competitive landscape within the pharmaceutical industry, with larger and more established companies dominating market share.

Opportunities

Kiniksa Pharmaceuticals Ltd can leverage various opportunities to further enhance its business and market presence. These opportunities include:

  • Growing demand for innovative pharmaceutical solutions, driven by an aging population and increasing prevalence of chronic diseases.
  • Expanding into emerging markets with less saturated competition, providing opportunities for market expansion and revenue growth.
  • Potential collaborations and partnerships with academic institutions and other pharmaceutical companies, fostering knowledge sharing and access to complementary expertise.
  • Advancements in technology and data analytics, enabling the company to enhance its research and development capabilities and optimize decision-making processes.

Threats

Kiniksa Pharmaceuticals Ltd must also consider various threats that may impact its operations and market position. These threats include:

  • Stringent regulations and compliance requirements in the pharmaceutical industry, increasing the cost and time involved in drug development and commercialization.
  • Intense competition from existing and emerging pharmaceutical companies, challenging the company's market share and pricing strategies.
  • Potential adverse effects of global economic downturns or recessions, affecting healthcare spending and demand for pharmaceutical products.
  • Rapidly evolving technologies and scientific advancements, requiring continuous investment in research and development to stay competitive.

Kiniksa Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Kiniksa Pharmaceuticals historical P/E ratio, EBIT multiple, and P/S ratio

Kiniksa Pharmaceuticals shares outstanding

The number of shares was Kiniksa Pharmaceuticals in 2023 — This indicates how many shares 71.923 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Kiniksa Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Kiniksa Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Kiniksa Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Kiniksa Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Kiniksa Pharmaceuticals stock splits

In Kiniksa Pharmaceuticals's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Kiniksa Pharmaceuticals.

Kiniksa Pharmaceuticals latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.08 -0.06  (21.57 %)2024 Q2
3/31/2024-0.17 -0.25  (-50.06 %)2024 Q1
12/31/2023-0.14 0.35  (345.1 %)2023 Q4
9/30/2023-0.17 -0.2  (-17.03 %)2023 Q3
6/30/2023-0.17 0.21  (222.88 %)2023 Q2
3/31/2023-0.21 -0.18  (14.97 %)2023 Q1
12/31/2022-0.24 0.06  (125.3 %)2022 Q4
9/30/20220.8 3.18  (298.4 %)2022 Q3
6/30/2022-0.45 -0.29  (35.76 %)2022 Q2
3/31/2022-0.41 -0.36  (13.21 %)2022 Q1
1
2
3

Eulerpool ESG Scorecard© for the Kiniksa Pharmaceuticals stock

Eulerpool World ESG Rating (EESG©)

52/ 100

🌱 Environment

58

👫 Social

45

🏛️ Governance

53

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Kiniksa Pharmaceuticals shareholders

%
Name
Stocks
Change
Date
4.17167 % The Vanguard Group, Inc.2,959,3866,34212/31/2023
4.09854 % Rubric Capital Management LP2,907,501-169,94812/31/2023
4.06431 % Fairmount Funds Management LLC2,883,221408,66012/31/2023
3.96050 % Baker Bros. Advisors LP2,809,577012/31/2023
3.79263 % BlackRock Institutional Trust Company, N.A.2,690,494152,84912/31/2023
2.21429 % Pictet Asset Management Ltd.1,570,816-33,90112/31/2023
2.17944 % State Street Global Advisors (US)1,546,096-215,57612/31/2023
1.48055 % Desnick (Robert)1,050,303214,1013/31/2023
1.26164 % Morgan Stanley & Co. LLC895,006255,08512/31/2023
1.01831 % Granahan Investment Management, LLC722,388188,17412/31/2023
1
2
3
4
5
...
10

Kiniksa Pharmaceuticals Executives and Management Board

Mr. Sanjiv Patel53
Kiniksa Pharmaceuticals Chairman of the Board, Chief Executive Officer (since 2015)
Compensation 6.11 M
Mr. John Paolini58
Kiniksa Pharmaceuticals Senior Vice President and Chief Medical Officer
Compensation 1.92 M
Mr. Eben Tessari41
Kiniksa Pharmaceuticals Chief Operating Officer, Senior Vice President
Compensation 1.92 M
Dr. Felix Baker54
Kiniksa Pharmaceuticals Lead Independent Director
Compensation 331,702
Mr. Thomas Malley54
Kiniksa Pharmaceuticals Independent Director
Compensation 301,002
1
2
3

Most common questions regarding Kiniksa Pharmaceuticals

What values and corporate philosophy does Kiniksa Pharmaceuticals represent?

Kiniksa Pharmaceuticals Ltd is driven by its core values of commitment, innovation, and patient-centricity. With a strong corporate philosophy, the company aims to bring transformative therapies to patients in need. Kiniksa Pharmaceuticals Ltd focuses on developing novel, targeted drugs to address unmet medical needs in immunology and inflammation. By harnessing scientific expertise and leveraging strategic collaborations, the company aims to deliver robust solutions for patients suffering from debilitating diseases. Kiniksa Pharmaceuticals Ltd is dedicated to improving patient outcomes, enhancing quality of life, and making a positive impact on the healthcare industry through its innovative and patient-centric approach.

In which countries and regions is Kiniksa Pharmaceuticals primarily present?

Kiniksa Pharmaceuticals Ltd is primarily present in the United States and focuses on the development and commercialization of innovative medicines. As a biopharmaceutical company, Kiniksa Pharmaceuticals Ltd operates in multiple states across the U.S., including its headquarters in Lexington, Massachusetts. With a mission to help patients with debilitating diseases, Kiniksa Pharmaceuticals Ltd has a strong presence within the American healthcare system, collaborating with healthcare professionals, researchers, and patients to provide targeted therapies for various medical conditions.

What significant milestones has the company Kiniksa Pharmaceuticals achieved?

Kiniksa Pharmaceuticals Ltd has achieved several significant milestones. The company successfully completed its initial public offering (IPO) in June 2018, raising approximately $202 million. In the same year, Kiniksa received approval from the U.S. Food and Drug Administration (FDA) for its first drug, ARCALYST®, to treat a rare and severe autoinflammatory disease called Deficiency of Interleukin-1 Receptor Antagonist (DIRA). Furthermore, Kiniksa Pharmaceuticals Ltd has expanded its pipeline by advancing various product candidates across multiple therapeutic areas, including immunology and oncology. These achievements demonstrate the company's commitment to developing innovative treatments and improving patient outcomes.

What is the history and background of the company Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company focused on discovering, developing, and commercializing therapies for patients living with debilitating diseases and unmet medical needs. Founded in 2015, the company is headquartered in Hamilton, Bermuda. Kiniksa Pharmaceuticals aims to address critical unmet needs in immunology and inflammation through its pipeline of innovative therapeutics. With a strong dedication to scientific excellence, the company leverages its expertise in biological insights, translational medicine, and clinical development to advance its proprietary pipeline. Kiniksa Pharmaceuticals Ltd. is committed to improving the lives of patients and delivering valuable solutions to the healthcare industry.

Who are the main competitors of Kiniksa Pharmaceuticals in the market?

Some of the main competitors of Kiniksa Pharmaceuticals Ltd in the market include AbbVie Inc., Novartis AG, Regeneron Pharmaceuticals Inc., and Bristol-Myers Squibb Company.

In which industries is Kiniksa Pharmaceuticals primarily active?

Kiniksa Pharmaceuticals Ltd is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Kiniksa Pharmaceuticals?

The business model of Kiniksa Pharmaceuticals Ltd focuses on developing and commercializing novel therapies for patients with debilitating diseases and unmet medical needs. Kiniksa Pharmaceuticals is dedicated to identifying and targeting key pathways involved in diseases to create innovative treatments. By utilizing its expertise in biology and immunology, the company aims to bring effective and differentiated therapies to market. Through research, clinical development, and strategic partnerships, Kiniksa Pharmaceuticals aims to improve the lives of patients and provide long-term value for its stakeholders.

What is the P/E ratio of Kiniksa Pharmaceuticals 2024?

The Kiniksa Pharmaceuticals P/E ratio is -132.16.

What is the P/S ratio of Kiniksa Pharmaceuticals 2024?

The Kiniksa Pharmaceuticals P/S ratio is 4.4.

What is the Quality Investing of Kiniksa Pharmaceuticals?

The Quality Investing for Kiniksa Pharmaceuticals is 1/10.

What is the revenue of Kiniksa Pharmaceuticals 2024?

The expected Kiniksa Pharmaceuticals revenue is 429.59 M USD.

How high is the profit of Kiniksa Pharmaceuticals 2024?

The expected Kiniksa Pharmaceuticals profit is -14.29 M USD.

What is the business model of Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals Ltd is a biopharmaceutical company focused on the development of therapies for serious diseases. Headquartered in Hamilton, Bermuda, the company has offices in the United States and Switzerland. The company consists of two main business segments. Firstly, Kiniksa Operations, which is responsible for the development and commercialization of therapies for patients with immune-mediated diseases. Secondly, the subsidiary VIBATIV, an antibiotic for adult patients with complicated skin and soft tissue infections. Kiniksa is currently developing a range of drugs that can be used for the treatment of various diseases, including autoinflammatory syndromes, autoimmune diseases, cancer, and pain therapy. The main product of Kiniksa is Rilonacept, a human Fc-fusion protein used for the treatment of fever in patients with cryopyrin-associated periodic syndromes (CAPS). In clinical trials, Rilonacept has proven to be an effective and safe medication. The company also has other drugs in the pipeline, including KPL-716, a monoclonal antibody developed for the treatment of Prurigo nodularis, a severe chronic itching disease. The drug is currently in phase III of clinical development. Kiniksa is also working on the development of drugs for the treatment of certain types of cancer and autoinflammatory diseases such as Still's syndrome and macrophage activation syndrome. Kiniksa's products aim to slow the progression of the disease and provide patients with a higher quality of life. In order to continue this innovative research and development, Kiniksa has also entered into strategic partnerships with other companies and institutions. Partners include MedImmune, a division of AstraZeneca, and Yale University. Overall, Kiniksa aims to improve the quality of life for patients with serious diseases by developing innovative therapies and medications. The company conducts rigorous research and development, collaborates closely with partners, and is committed to the highest standards of patient safety and efficacy of its products. Through innovative therapeutic approaches and partnerships with leading academic institutions in the global market, Kiniksa has earned a reputation for the highest medical standards and excellent patient care. Thanks to differentiated therapy approaches and flexibility towards new insights and advancements in techniques and sciences, Kiniksa is always on the right side of the future and developments, thus exposed to strong growth potential.

What is the Kiniksa Pharmaceuticals dividend?

Kiniksa Pharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does Kiniksa Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for Kiniksa Pharmaceuticals or the company does not pay out a dividend.

What is the Kiniksa Pharmaceuticals ISIN?

The ISIN of Kiniksa Pharmaceuticals is BMG5269C1010.

What is the Kiniksa Pharmaceuticals WKN?

The WKN of Kiniksa Pharmaceuticals is A2JMVJ.

What is the Kiniksa Pharmaceuticals ticker?

The ticker of Kiniksa Pharmaceuticals is KNSA.

How much dividend does Kiniksa Pharmaceuticals pay?

Over the past 12 months, Kiniksa Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Kiniksa Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Kiniksa Pharmaceuticals?

The current dividend yield of Kiniksa Pharmaceuticals is .

When does Kiniksa Pharmaceuticals pay dividends?

Kiniksa Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Kiniksa Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Kiniksa Pharmaceuticals located?

Kiniksa Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Kiniksa Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Kiniksa Pharmaceuticals from 10/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/20/2024.

When did Kiniksa Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/20/2024.

What was the dividend of Kiniksa Pharmaceuticals in the year 2023?

In the year 2023, Kiniksa Pharmaceuticals distributed 0 USD as dividends.

In which currency does Kiniksa Pharmaceuticals pay out the dividend?

The dividends of Kiniksa Pharmaceuticals are distributed in USD.

All fundamentals about Kiniksa Pharmaceuticals

Our stock analysis for Kiniksa Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Kiniksa Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.